Cancer Immunotherapy Clinic

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...

The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.

Recruiting

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple M...

DLTs will be assessed during the DLT interval (ie, within 21 days immediately after bb2121 infusion). DLTs are defined as any bb2121 related Grade 3 to 5 toxicity.

Recruiting

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refrac...

Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab.

Recruiting

Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant...

Will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (version 5.0 beginning April 1, 2018). Safety and tolerability will be assessed by summarizing all relevant parameters including AEs, serious ...

Recruiting

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

Recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection ...

The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.

Recruiting

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...

Incidence of adverse events (AEs) observed across STRO-001 dose levels

Recruiting

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Only patients in cohort 2, who achieve testosterone recovery to non-castrate levels (>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA < nadir + 2 ng/mL at 15 months from the start of radiotherap...

Recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Ca...

Recruiting

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refract...

ORR is defined as stringent complete response (sCR) + complete response (CR) + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria for all ...

Recruiting